SS-31 (Elamipretide) is a synthetic, mitochondria-targeted tetrapeptide developed by researchers Hazel Szeto and Peter Schiller.
🔬 Studied for: Mitochondrial-Disease Research
💊 Also studied for: Cardiac & Age-Related Research
🧪 Not FDA-approved — sold strictly for laboratory research
📈 No standardized human dosage established in published literature
SS-31 (Elamipretide) is a synthetic, mitochondria-targeted tetrapeptide developed by researchers Hazel Szeto and Peter Schiller. It is among the more clinically advanced compounds in this category, having progressed through multiple human clinical trials for mitochondrial disease.
SS-31 selectively binds cardiolipin, a phospholipid unique to the inner mitochondrial membrane, where it is studied for stabilizing mitochondrial cristae structure and improving electron-transport-chain efficiency — a distinct mechanism from peptides that act at cell-surface receptors.
These are effects SS-31 (Elamipretide) has been studied for in available preclinical and early research — not claims about guaranteed outcomes.
SS-31 has been studied in human clinical trials for Barth syndrome, a rare genetic mitochondrial disorder, and in research on mitochondrial dysfunction more broadly, giving it a more developed clinical research record than most peptides in this category.
Beyond rare-disease research, SS-31 has been studied in models of heart failure and age-related mitochondrial decline, reflecting broader interest in cardiolipin-targeted therapeutics for conditions involving mitochondrial dysfunction.
Doses used in published clinical trials are documented in that trial literature and are specific to those regulated study protocols; no FDA-approved commercial dosage exists for SS-31 research material.
Compound X does not provide dosing recommendations. SS-31 (Elamipretide) is sold for laboratory research use only and is not intended for human consumption.
As a clinically trialed compound, SS-31/Elamipretide has published human safety data from its trial programs, including reports of injection-site reactions; it has not, however, received full FDA approval for a marketed indication, and research-grade material outside those regulated trials has not undergone the same quality controls.
No. SS-31 (Elamipretide) is not FDA-approved for any indication and is sold strictly as a research chemical, not a medication or dietary supplement.
Mitochondrial-Disease Research — SS-31 has been studied in human clinical trials for Barth syndrome, a rare genetic mitochondrial disorder, and in research on mitochondrial dysfunction more broadly, giving it a more developed clinical research record than most peptides in this category.
In the US, UK, Canada and Australia, SS-31 (Elamipretide) is generally sold labeled "for research use only, not for human consumption." It is not approved as a dietary supplement or medication in any of these countries.
SS-31/Elamipretide clinical trial data is indexed on PubMed under "Elamipretide SS-31 mitochondrial" and "Szeto-Schiller peptide cardiolipin."
Compare current prices, purity testing claims and coupon codes across every vendor Compound X tracks.
New guides, vendor comparisons and compound breakdowns every week.